Czechia· CZ-0250233
ULTOMIRIS
A ravulizumab product containing ravulizumab, registered in Czechia by Alexion Europe SAS, Levallois-Perret. The same ATC class is registered in 12 of our 19 countries.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
Where it is registered
Ravulizumab is registered in 12 of 19 countries.
Countries holding a registration under ATC L04AJ02 (ravulizumab), each read from that country’s own register.
- This record: Czechia, from SÚKL (Czech Republic)
- 7 of them publish a price we can compare per daily dose
Ravulizumab · ATC L04AJ02
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
SÚKL (Czech Republic)- Active substance
- RAVULIZUMAB
- Manufacturer
- Alexion Europe SAS, Levallois-Perret
- Country
- Czechia (CZ)
- ATC code
- L04AJ02
- ATC class
- Ravulizumab
- Defined daily dose
- 70 mg, P
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- September 28, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
2 interactions on record for ravulizumab.
Graded by severity as the source publishes them — 2 minor. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ravulizumab · interactions on record
2 records
Same medicine, other countries
Ravulizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumUltomiris 1100 mg/11 mlAlexion Europe
- FinlandUltomirisAlexion Europe SAS
- NorwayUltomirisAlexion Europe SAS (2)
- SwedenUltomiris 1100 mg/11 ml Koncentrat till infusionsvätska, lösningAlexion Europe SAS
- IcelandULTOMIRISAlexion Europe SAS
- PolandUltomirisAlexion Europe SAS
- IrelandUltomiris 300 mg/3 mL concentrate for solution for infusionAlexion Europe S.A.S.
- United StatesUltomirisAlexion Pharmaceuticals Inc.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Ultomiris
- Liechtenstein · Ultomiris
- Norway · Ultomiris
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9fbd538e-1d74-4520-b3c4-a31777f9be45 GET /v1/drugs/9fbd538e-1d74-4520-b3c4-a31777f9be45?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "INF CNC SOL",
"source": "sukl",
"strength": "1100MG/11ML",
"pack_size": "1X11ML",
"substance": "RAVULIZUMAB",
"cz_kod_sukl": "0250233",
"product_type": "BT",
"substance_codes": "21591",
"registration_state": "R",
"registration_number": "EU/1/19/1371/003"
}See everything about ravulizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.